Evidence map›Paper›PMID 33582212›Full record

ArticleCancer letters2021

Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.

Kun Wang, Theodoros Michelakos, Bing Wang, Zikun Shang, Albert B DeLeo, Zhenfeng Duan, Francis J Hornicek, Joseph H Schwab, Xinhui Wang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Effect of Disulfiram on the Reproductive Capacity of Female Mice.International journal of molecular sciences · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kun WangDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA; Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Theodoros MichelakosDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Bing WangDepartment of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Zikun ShangDepartment of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Albert B DeLeoDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Zhenfeng DuanThe Sarcoma and Chordoma Molecular Biology Laboratory, Orthopaedic Surgery, The University of California, Los Angeles, CA, 90095, USA.
Francis J HornicekThe Sarcoma and Chordoma Molecular Biology Laboratory, Orthopaedic Surgery, The University of California, Los Angeles, CA, 90095, USA.
Joseph H SchwabDepartment of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. Electronic address: jhschwab@mgh.harvard.edu.
Xinhui WangDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. Electronic address: xwang30@mgh.harvard.edu.
Harvard University · USUniversity of California, Los Angeles · USCentral South University · CN

Funding

Prevention of post-therapy breast cancer metastasisR01CA226981 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, XINHUI · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA226981
6 · The paper itself

Abstract

Overcoming the radiosensitivity of chondrosarcoma (CS), the second most common primary bone tumor, is needed. Radioresistance is attributed to cancer stem cells (CSCs) in many malignancies. Disulfiram (DSF), an FDA-approved anti-alcoholism drug, complexed with Cu (DSF/Cu) can radiosensitize epithelial CSCs. This prompted us to investigate the radiosensitizing effect of DSF/Cu on CS CSCs (CCSCs). The radiosensitizing effects of DSF/Cu on CCSCs were investigated in vitro using cell lines SW1353 and CS-1. Stemness was identified independently by flow cytometry for CCSCs (ALDH

Indexed as

AC133 AntigenAldehyde DehydrogenaseAnimalsBone NeoplasmsCell Line, TumorChondrosarcomaCopperDisulfiramDose Fractionation, RadiationFemaleHumansMiceNeoplastic Stem CellsRadiation-Sensitizing AgentsXenograft Model Antitumor AssaysAC133 AntigenAldehyde DehydrogenaseCopperDisulfiramRadiation-Sensitizing AgentsCCSCsNF-κBRadioresistanceRadiosensitizingStemness

Identifiers

PMID33582212
PMCPMC8969896
OpenAlexW3127223248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.